PAJOUHESH HASSAN,SIMONSON ERIC,ZHOU YUANXI,GALEMMO ROBERT,GRIMWOOD MIKE,ZHU YONGBAO,CHAHAL NAVJOT,HOLLAND RICHARD
申请号：
NZ59826910
公开号：
NZ598269A
申请日:
2010.09.17
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Such conditions may include: pain, epilepsy, Parkinson&rsquos disease, depression, psychosis, or tinnitus. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I). example compounds include: N-(2-methyl-2-(3-(trifluoromethyl)phenylsulfonyl)propyl)-3-(trifluoromethyl)benzenesulfonamide, 3-chloro-4-fluoro-N-(2-methyl-2-(3-(trifluoromethyl)phenylsulfonyl)propyl)benzamide, 6-(trifluoromethyl)-N-(((1S,3S)-3-(3-(trifluoromethyl)phenylsulfonyl)cyclobutyl)methyl)imidazo[1,2-a]pyridine-2-carboxamide, 3-(isopropylsulfonyl)-5-(trifluoromethyl)-N-((1R,4R)-4-(3-(trifluoromethyl)phenylsulfonyl)cyclohexyl)picolinamide, and 2-chloro-6-(trifluoromethyl)-N-((1S,4S)-4-(3-(trifluoromethyl)phenylsulfonyl)cyclohexyl)nicotinamide.
